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The emergence of a swine influenza virus (H1N1) pandemic strain earlier this year prompted a 
huge worldwide effort to produce swine flu vaccines in time for the winter flu season. Justine 
Davies reports.Last month, infectious disease experts 
gathered in Melbourne, Australia, to 
decide on which influenza virus strains 
to include in the seasonal flu vaccine 
for the Southern hemisphere’s flu sea-
son. Such gatherings, organized by the 
World Health Organization (WHO), are 
held twice a year. But this meeting was 
unusual because discussion of the sea-
sonal flu vaccine was overshadowed 
by discussion of vaccine production to 
combat the new H1N1 pandemic swine 
flu strain.
In mid to late March this year, a new 
influenza A virus (subtype H1N1) of swine 
origin emerged in Mexico and the United 
States, quickly spreading to more than 
30 countries by mid-May. In mid-June, 
the WHO declared the first flu pandemic 
in four decades, and the race was on to 
produce sufficient vaccine against the 
H1N1 virus by October 2009, the start of 
the Northern hemisphere flu season. In a 
world far removed from that of the father 
of vaccination, Edward Jenner, the col-
lective effort of scientists worldwide has 
done just that. “The vaccine groups have 
done magnificently,” says virologist John 
Oxford at Queen Mary School of Medi-
cine in London. “Over 30,000 people 
have devoted the last 40 years to devel-
oping these vaccines and their efforts 
have come to fruition in the production 
of the swine flu vaccine.”
Most of the swine flu vaccines cur-
rently available were produced by the 
standard method of culturing the virus in 
chicken eggs. The vaccine is then made 
from the whole killed virus, or by treat-
ing the virus with ether or detergent to 
produce a subunit vaccine. For example, 
the Novartis swine flu vaccine, Focetria, 
is a subunit vaccine produced in eggs 
and contains the hemagglutinin (HA) and 
neuraminidase (NA) surface antigens of 
the H1N1 influenza virus. But influenza 
viruses that thrive in humans are hard to 
grow in chicken eggs, and the eggs are expensive and in short supply. So differ-
ent labs worldwide are finding new ways 
to boost the yield of virus from eggs and 
are developing innovative methods to 
avoid the use of eggs altogether by cul-
turing the virus in cell lines. About 10% 
of currently available swine flu vaccines 
have been made using new methods. 
For example, MedImmune’s vaccine is a 
live attenuated virus produced by engi-
neering a cold adapted influenza virus 
(that doesn’t replicate at human body 
temperature) to express genes encoding 
the hemagglutinin and neuraminidase of 
the H1N1 virus. Baxter’s vaccine is pro-
duced by culturing the virus in a Vero 
cell line, rather than in eggs. Novartis is 
also developing a swine flu vaccine using 
virus cultured in an MDCK cell line.
Increasing the Yield
A key way to increase virus yield from 
eggs is the classical reassortment 
method. In this method, the new influ-
enza virus is injected into the allantoic 
cavity of a 10- to 12-day-old fertilized 
chick egg along with an influenza virus 
known to grow well in eggs, usually A/
PR/8/34 (known as PR8) for influenza A 
virus strains. The hope is that the eight 
genes in each of the two viruses will 
reassort resulting in a virus that contains 
six genes for rapid growth from the PR8 
strain and the two genes encoding the 
hemagglutinin and neuraminidase sur-
face antigens from the new virus.
“After the first 42 hour incubation 
period there are potentially 256 combi-
nations of genes amongst the resulting 
reassortants,” says Doris Bucher of New 
York Medical School. To narrow these 
down and promote “positive selection 
for growth and negative selection for 
[PR8] surface antigens, the reassortants 
undergo subsequent incubation cycles 
where antibodies to PR8 surface anti-
gens, HA and NA, are added.” By the end 
of this process, reassortants expressing Cell 139antigens from PR8 should have been 
removed, leaving only reassortants with 
the surface antigens of the new virus. 
Lastly, these desired reassortants are 
cloned and amplified.
“Reverse genetics is the other way 
of producing a rapidly growing strain 
with the required antigens,” says Rob-
ert Webster, an influenza expert at St. 
Jude’s Children’s Research Hospital in 
Memphis, Tennessee. This method was 
brought into play a couple of years ago 
when trying to culture the avian influenza 
virus H5N1, the emergence of which had 
sparked fears of a possible pandemic. “It 
just wouldn’t grow using any of the other 
methods,” he notes.
Vaccine Production from A to Z
Producing a vaccine to a new strain of 
influenza virus follows a standard pro-
cess. At the first report of any outbreak, 
the WHO’s Global Influenza Surveillance 
Network starts working to identify the 
culprit virus (http://www.who.int/csr/
disease/influenza/surveillance/en/index.
html). This network continually monitors 
changes in circulating viruses. Identifica-
tion of a local virus type and subtype is 
carried out at national influenza centers 
and samples requiring further analysis 
are sent on to a collaborating center. 
“The global flu network was estab-
lished 60 years ago with the original 
influenza center in London,” says Alan 
Hay, director of the London collaborat-
ing center. This center is one of five, with 
others in Tokyo, Melbourne, Memphis, 
and Atlanta. “The collaborating centers 
define antigenic drift both subjectively, 
by testing the virus against ferret antise-
rum to previous viruses, and objectively, 
by sequencing the viral genome. These 
two methods combine to give very reli-
able data,” says Hay. Using these tech-
niques the US Center for Disease Control 
and Prevention (CDC) in Atlanta, Georgia 
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new H1N1 swine flu virus by the end of 
April this year, just 6 weeks after the first 
cases were reported.
Then “the race was on between the 
collaborating centers and other, mainly 
academic, laboratories to culture the 
strain which grew the quickest for use 
in a vaccine,” says Webster. Influenza 
viruses are quasispecies with many 
slightly different variants and “at the end 
of the culture process it is hoped that 
you can fish out a rapidly growing virus 
that contains the antigens you are inter-
ested in for the companies to use as their 
seed strain for vaccine manufacture,” 
he says. Each lab chooses their own 
method to culture a rapid growth strain, 
but as Webster points out “there is a 
huge amount of collaboration between 
the laboratories at this stage, involving a 
lot of talking and swapping notes.”
It was Doris Bucher’s group, using the 
classical reassortment method, that pro-
duced the virus that was selected as the 
seed strain to produce vaccines against 
H1N1. Bucher explains, “We played a 
trick when we made H1N1, and dressed 
it up in H3N2’s clothing. Instead of mix-
ing the wildtype virus identified by CDC 
with PR8, we used one of our favorite 
reassortants, NYMC X-157.” This reas-
sortant has the desired six genes for 
rapid growth from PR8, with the hemag-
glutinin and neuraminidase coming from 
an old H3N2 New York strain. To ensure 
that reassortants in the seed strain only 
contained swine influenza virus surface 
antigens, Bucher added antibodies 
directed against the surface antigens of 
X-157 during the culture process.
A number of candidate H1N1 seed 
strains were made by other labs using 
reverse genetics, but these did not grow 
as well as Bucher’s strain. “This may 
be because the classic reassortment 
method allows for a ‘swarm of variants’ 
so there is a greater chance that one in 
this swarm will grow well. The reverse 
genetics method is more targeted, so 
there might be less variation,” explains 
Bucher.
The candidate seed strains made by 
different labs are sent to one of the five 
collaborating centers, which test that 
the seed strains produce robust immune 
responses using ferret antiserum to the 
wild-type virus. Among the strains that 
produce a good response, the strain that 450 Cell 139, October 30, 2009 ©2009 Elsegrows the quickest is selected as the 
seed strain, which is then made avail-
able to pharmaceutical companies for 
the mass manufacture of vaccine.
“The 2009 H1N1 influenza virus is 
a new virus, but the process for mak-
ing vaccine is the same as for seasonal 
strains,” says Anthony Fauci, Director 
of the US National Institute of Allergy 
and Infectious Diseases, part of the US 
Department of Health and Human Ser-
vices (DHHS) (http://www3.niaid.nih.gov/
topics/Flu). “The HHS provides funds and 
resources to allow production of sea-
sonal flu vaccines on a yearly basis and 
the companies collaborate as part of an 
agreement to provide resources when 
required to rapidly produce a vaccine for 
a pandemic,” he says.
From Academia to Pharma
Once the chosen seed strain reaches 
pharmaceutical companies, the scien-
tists at big pharma continue to select 
rapidly growing strains. “Although phar-
maceutical companies are working hard 
to provide a vaccination beneficial to 
human health, they are also trying to 
make a profit,” says Webster. Webster 
adds, “there has never been a reason 
to force companies to collaborate and 
share information, as the seed stock 
from the academic labs is always very 
good. With swine flu, once Doris Bucher 
had done her work, the growth of the 
virus was about as good as it gets.”
Once companies have successfully 
cultured their seed virus, they treat it 
to make an inactivated whole virus or a 
subunit vaccine. Adjuvants can be added 
to increase the immunogenicity of the 
vaccine, with the advantage of less vac-
cine being needed to produce the same 
antibody response. This is of huge ben-
efit when dealing with a pandemic when 
vaccine may be in short supply. Two of 
the three swine flu vaccines approved in 
Europe contain adjuvant, but currently 
none of the US vaccines do. The US has 
adjuvants for use in an emergency, but 
due to the good immunogenicity of the 
swine flu vaccines, adjuvants may not be 
needed.
From identifying the swine influenza 
virus in April to regulatory approval for 
the vaccines took only 6 months. Cur-
rently, four H1N1 vaccines—from CSL Ltd., 
MedImmune LLC, Novartis, and Sanofi vier Inc. Pasteur—have been approved by the US 
Food and Drug Administration (FDA) (http://
www.fda.gov/BiologicsBloodVaccines/
Vaccines/ApprovedProducts/ucm181950.
htm). And in Europe, H1N1 vaccines from 
Novartis and GlaxoSmithKline (GSK) 
were approved by the European Medi-
cines Agency on September 29th, with 
Baxter’s vaccine receiving approval on 
October 6th. (http://www.emea.europa.
eu/pdfs/general/direct/pr/60258209en.
pdf).
A Lack of Innovation
It seems that this system has worked 
seamlessly, but there are concerns that it 
could have been better. Ninety percent of 
the currently available swine flu vaccines 
were made using chicken eggs, with only 
10% using newer, quicker methods (that 
is, MedImmune’s live attenuated vac-
cine, and the vaccines produced in cell 
culture by Baxter and Novartis).
“There are many advantages of a 
cell culture system,” says Noel Barrett, 
Vice-President R&D Vaccines at Baxter 
Innovations. “It obviates the need for the 
hundreds of millions of fertilized eggs 
per year. It is also more likely to be ster-
ile than production in eggs.” In addition 
“the cells can be stored in the freezer 
and brought into production whenever 
they are needed.” Using cell culture also 
circumvents the time-consuming need 
to genetically modify virus to grow in 
eggs. For their swine flu vaccine, Baxter 
simply grew the wild-type virus in their 
Vero cell line, which meant that they did 
not have to wait for the academic labs 
to grow a seed strain. But despite these 
advantages, getting this method off the 
ground required considerable invest-
ment. “The cost of building new facilities 
is high and has to be written off over a 
period of approximately 20 years, which 
obviously reduces profit margins,” says 
Barrett, “and there is the high cost of 
conducting clinical trials to get the novel 
vaccines licensed.”
“The need to make a profit and the 
high costs of developing new vaccines 
means that innovations often come from 
academics rather than companies,” says 
Mike Skinner, head of the Vaccine Vec-
tor Group at Imperial College in London. 
“In general companies look at the bigger, 
easier targets,” he says “but that is not 
what drives new vaccine development. 
When the targets are harder, academic 
labs can afford to look at radical new 
methods that may work and the ‘maybe 
this will work’ approach drives vaccine 
development forward.”
Webster notes that the diminished inter-
est of big pharma in flu vaccines has been 
“problematic in the past.” “The lack of 
financial incentives has meant that most 
companies stopped producing flu vac-
cines in the US, this means the US has 
to source most of its vaccines offshore,” 
says Webster. In the 2004–2005 regular 
flu season, for example, there was only 
one company in the US producing vac-
cine. However, as concerns about a pos-
sible avian flu pandemic increased, the US 
government boosted its investment in flu 
vaccine production. Webster notes, “We 
are still currently dependent on offshore 
vaccine production with the consequence 
that if the swine flu virus had started killing 
people in those [offshore] countries their 
commitment to provide vaccine to the US 
could have been overruled.”
Addressing the Problem
The US DHHS started to address the 
lack of innovation in flu vaccine produc-
tion through its BARDA unit (Biomedical 
Advanced Research and Development 
Authority; http://www.hhs.gov/aspr/barda). 
Launched in 2000, BARDA coordinates the 
development, production, and purchase of 
the necessary vaccines, drugs, and diag-
nostics to combat public health emergen-
cies. Recently, BARDA has ramped up its 
efforts to boost flu vaccine production and 
to foster development of flu vaccines using 
new methods.
BARDA has pumped more than $5.5 
billion into influenza vaccine develop-
ment and production over the last 4 
years. For example, in 2007 alone, $120 
million was given to onshore companies 
to increase production of egg-based flu 
vaccines in the US. But concerns that the egg-based method is too unreliable 
and sluggish to be ideal for pandemic 
situations prompted an extra injection of 
funds to stimulate companies to speed 
innovations in flu vaccine development.
Michael Perdue, director of the Division 
of Influenza and Emerging Diseases at 
BARDA, says companies receiving such 
funds include GSK, which is developing a 
new avian cell line in which to grow avian 
influenza virus. “The idea is that it would 
produce very high levels of an avian ori-
gin virus compared to mammalian cell 
lines,” says Perdue. “We are funding 
Novartis, GSK and Intercell for develop-
ment of adjuvants,” he adds. In January 
this year, Novartis received nearly $500 
million from BARDA to develop an MDCK 
cell culture method for flu vaccine pro-
duction in the US. But the funds are not 
limited to US companies: Baxter, which 
is based in Vienna, Austria, also received 
BARDA funds to help in the process of 
gaining FDA approval for its vaccine pro-
duced in cultured cells.
Another company to benefit from 
DHHS’s innovation funding is Protein 
Sciences in Connecticut, whose subunit 
seasonal flu vaccine consists of pure 
hemagglutinin produced in a baculovirus 
expression vector system. Manon Cox, 
the Chief Operating Officer at Protein 
Sciences, welcomes the new funds but 
cautions that “The support is going to 
the old as well as the new technologies, 
which means that larger companies have 
no incentive to explore new technologies 
if they are getting money for continuing 
with the old one.” However, she realizes 
that there is no easy solution: “You can’t 
throw away your old shoes before you 
buy a new pair,” she says.
From Pharma to the Clinic
Pilot (investigational) lots of the different 
H1N1 flu vaccines developed by phar-
maceutical companies are sent back to Cell 139academic and government labs for clini-
cal trials where they are tested for safety 
and efficacy. As the swine flu vaccines 
are produced using methods already 
tested with seasonal flu vaccines, they 
are unlikely to produce unforeseen safety 
issues. However, they have been thor-
oughly tested on thousands of people 
prior to approval. “One of the reasons 
for such rigorous testing may be to reas-
sure the public that the vaccine is indeed 
safe,” says virologist John Oxford.
The results of the first clinical trials 
of the subunit swine flu vaccines were 
published in the New England Journal 
of Medicine in early September (http://
content.nejm.org/cgi /content / fu l l /
NEJMe0908224). These studies showed 
that the vaccines could be effective even 
if used sparingly; just a single dose was 
immunogenic, although a two-dose 
regime produced greater antibody titers. 
In addition, the subunit vaccine contain-
ing adjuvant was immunogenic at half 
the dose of the subunit vaccine without 
adjuvant. So far, says Fauci, studies have 
shown that the vaccine is well tolerated 
with little in the way of safety issues. In 
addition, even though the vaccines have 
been produced by several different com-
panies the responses to them in trials 
have been equitable.
Just 6 months after the H1N1 swine 
flu virus was identified, vaccines have 
been approved for use in the US, many 
European countries, as well as Australia, 
China, and Japan. Other countries will 
soon follow suit. From analyzing figures 
on production since May 2009, the WHO 
estimates that 3 billion doses of flu vac-
cine can now be produced per year in a 
pandemic. With flu season starting, the 
scientists’ job may be done, but the race 
to vaccinate as many people as pos-
sible against swine flu and seasonal flu 
has just begun for public health officials 
around the globe.
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